Gilead Sciences Inc (NASDAQ:GILD)
| 65.61 BATS BZX Real-Time Price As of 3:16pm ET |  +0.99 / +1.53%Today’s Change | 56.56 Today|||52-Week Range 85.97 | +12.62% Year-to-Date |
GILD Regular Dividend: GILD will begin trading ex-dividend on 03/12/21 with a $0.71 dividend payable to shareholders of record as of 03/15/21.
Latest GILD News | Press Releases
| Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study 10:15am / Zacks.com - Paid Partner Content | Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss Feb 26 / Zacks.com - Paid Partner Content |
| Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report? Mar 06 / Zacks.com - Paid Partner Content | FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses Feb 25 / Zacks.com - Paid Partner Content |
| After 2 Licensing Deals Will GlaxoSmithKline Acquire Vir? Mar 06 / MotleyFool.com - Paid Partner Content | The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Deere, T-Mobile US and Gilead Sciences Feb 24 / Zacks.com - Paid Partner Content |
| 3 A-Rated Value Stocks to Buy Right Now Mar 05 / StockNews.com - Paid Partner Content | Top Analyst Reports for Apple, P&G, Deere & Others Feb 23 / Zacks.com - Paid Partner Content |
| The Most Popular Guru Buys of the 4th Quarter Mar 04 / GuruFocus News - Paid Partner Content | Is Galapagos Stock a Bad-News Buy Right Now? Feb 23 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 64.62 |
| Today’s open | 64.54 |
| Day’s range | 63.95 - 66.66 |
| Volume | 649,644 |
| Average volume (3 months) | 9,052,812 |
| Market cap | $81.2B |
Data as of 3:16pm ET, 03/08/2021
Growth & Valuation
| Earnings growth (last year) | -97.69% |
| Earnings growth (this year) | -0.14% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | +10.39% |
| P/E ratio | 655.8 |
| Price/Sales | 2.99 |
| Price/Book | 4.45 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ILMNIllumina Inc | -13.91 | -3.49% |
| MRNAModerna Inc | -8.67 | -6.55% |
| BIIBBiogen | +3.30 | +1.22% |
| AMGNAmgen | +1.34 | +0.59% |
Data as of 3:16pm ET, 03/08/2021
Financials
| Next reporting date | May 4, 2021 |
| EPS forecast (this quarter) | $2.03 |
| Annual revenue (last year) | $24.6B |
| Annual profit (last year) | $123.0M |
| Net profit margin | 0.50% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Foster City, California |
Forecasts
